Simoa human nf light advantage kit

Biomarker analyses have been previously described and based on the PPMI biologics manual (Marek et al., 2018 (link)). CSF was collected by standardized lumbar puncture procedures. Measurements of Aβ₄₂ and t-tau were analyzed by using the xMAP-Luminex platform with INNOBIA AlzBio3 immunoassay kit–based reagents (Fujirebio-Innogenetics, Ghent, Belgium) at Penn (Kang et al., 2013 (link)). Additionally, CSF total α-syn levels were measured by BioLegend (San Diego, CA, United States) by means of a commercially accessible and previously described sandwich immunoassay. Serum NFL was quantified by the Simoa Human NF-light Advantage Kit (Quanterix, Lexington, MA, United States) using the Single Molecule Array technology in a fully automated SIMOA HD-1 analyzer. Biochemical analyses of uric acid have been carried out in Covance laboratories in a uniform fashion, as per the study protocol.

Venous blood samples (10 mL) were collected from the medial cubital vein into EDTA tubes at three different time points: baseline (test 1), one week before training (test 2), and one week after completing the training program (test 3). For each sample, the serum fraction was collected, aliquoted into multiple 0.5 mL cryovial-sterilized tubes, and then stored at −80 °C until analyzed at the Immunology Department of Hospital Ramón y Cajal (Madrid, Spain). Serum NfL concentrations were quantified using single-molecule array technology (SiMoA; Quanterix Corp) with a SR-X instrument (Quanterix, Lexington, MA, USA) and the SiMoA human NF-light Advantage Kit (Quanterix, Billerica, MA, USA). A detailed protocol and data specific to serum NfL are comprehensively described in one of our prior studies [21 (link)].